Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model.
To date, most molecular epidemiological studies on gene polymorphisms in cancer have focused on the risk of development and susceptibility to cancer. However, interindividual genetic variation may contribute greatly to the treatment outcome and prognosis of cancer by affecting the interaction between cancer cells and hormones, growth factors and factors influencing the tumor microenvironment. In prostate cancer, several recent molecular epidemiological studies suggested the possibility of predicting treatment outcome and prognosis using genetic polymorphisms. Candidate genes are hormone-related, oncogenes, tumor-suppressor and cell cycle-growth control-related genes, as well as genes related to immune response, inflammatory change, neovasculization, and the extracellular matrix, genes involved in drug and xenobiotic metabolism and genes involved in DNA repair and genome stability. There remain a huge number of candidate genes whose polymorphisms may affect the progression and treatment outcome of various kinds of cancer, including that of prostate cancer.
Habuchi
Tomonori
T
Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan. thabuchi@doc.med.akita-u.ac.jp
D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics*
D009363:Neoplasm Proteins